SpringWorks Therapeutics Inc logo

SWTX

SpringWorks Therapeutics Inc

$28.14

Earnings Summary

Revenue
$0.35Mn
Net Profits
$-69.05Mn
Net Profit Margins
-19841.95%

Highlights

Revenue:

SpringWorks Therapeutics Inc’s revenue jumped +Inf% since last year same period to $0.35Mn in the Q2 2022. On a quarterly growth basis, SpringWorks Therapeutics Inc has generated -93.04% fall in its revenue since last 3-months.

Net Profits:

SpringWorks Therapeutics Inc’s net profit fell -46.88% since last year same period to $-69.05Mn in the Q2 2022. On a quarterly growth basis, SpringWorks Therapeutics Inc has generated -11.73% fall in its net profits since last 3-months.

Net Profit Margins:

SpringWorks Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -19841.95% in the Q2 2022. On a quarterly growth basis, SpringWorks Therapeutics Inc has generated -1505.31% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the SpringWorks Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.2
EPS Estimate Current Year
-1.2

Highlights

EPS Estimate Current Quarter:

SpringWorks Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.2 - a -17.65% fall from last quarter’s estimates.

EPS Estimate Current Year:

SpringWorks Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.2.

Key Ratios

Key ratios of the SpringWorks Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-0.36
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. SpringWorks Therapeutics Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. SpringWorks Therapeutics Inc’s return on equity (ROE) stands at -0.36.

Dividend Per Share (DPS):

SpringWorks Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-1.02
-1.26
-23.53%

Company Information

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.

Organisation
SpringWorks Therapeutics Inc
Employees
78
Industry
Health Technology